Medically reviewed by Jamin Brahmbhatt, MD Key Takeaways Complement 3 glomerulopathy (C3G) is diagnosed with a combination of ...
Dianthus achieved its NASDAQ listing last year via a merger with Magenta Therapeutics. The company is focused on development of a single drug candidate, DNTH-103, which targets the complement system, ...